Skip to main content

Table 3 Objective response to talabostat.

From: Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

Age/Sex
(Patient No.)
M classification at enrollmenta Metastatic sites at enrollment Prior Tx for
Stage IV diseaseb
Best response to prior Tx Response to talabostat Duration of Response (days)
54/F
(01-003)
M1b Skin, lung Tumor peptide heat shock (Vitespen) PD PR 151
46/M
(04-002)
M1b Lung Sargramostim PD PR 62
63/M
(04-003)
M1b Lung None NA PR 287
61/F
(06-001)
M1c Subcutaneous tissue, stomach, lymph node(s), visceral Temozolomide, thalidomide SD PR Unknownc
53/M
(09-014)
M1c Regional lymph node(s), liver None NA PR 176
58/F
(12-003)
M1c Lymph nodes beyond regional, lung, abdominal wall None NA PR 141
  1. Tx = treatment; PD = progressive disease; PR = partial response; NA = not applicable; SD = stable disease
  2. a M1a: Distant skin, subcutaneous, or nodal metastases; M1b: Lung metastases; M1c: all other visceral metastases. Baseline LDH levels were also used in this classification.
  3. b Includes chemotherapy and/or immunotherapy.
  4. c The patient was lost to follow-up.